Kiadis Pharma signs license agree­ment with Hospira to com­mer­cial­ize ATIR™ in Europe and Asia – Partnership would advance inno­v­a­tive stem cell trans­plant prod­uct

Kiadis Pharma, a bio­phar­ma­ceu­ti­cal com­pa­ny based in The Netherlands, announced that it has entered into a licens­ing agree­ment with Hospira, Inc. (NYSE: HSP), a glob­al spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny, to devel­op and com­mer­cial­ize Kiadis Pharma’s ATIR™.  ATIR™ is a per­son­al­ized hema­tol­ogy prod­uct designed for blood can­cer patients in need of allo­gene­ic bone mar­row trans­plan­ta­tion who can­not locate a matched donor. The prod­uct will enable a mis­matched fam­i­ly mem­ber to act as donor and is being devel­oped to reduce trans­plant relat­ed mor­tal­i­ty caused by infec­tions and graft-ver­sus-host dis­ease.

Under the terms of the agree­ment, Hospira is grant­ed exclu­sive mar­ket­ing rights to ATIR™ for Europe, the Middle East, Africa, Australia, Japan and parts of Asia.  Kiadis Pharma main­tains all rights to ATIR™ for the rest of the world. The finan­cial terms include an undis­closed upfront pay­ment and par­tial fund­ing of the ATIR™ reg­is­tra­tion clin­i­cal tri­al cur­rent­ly ongo­ing in Europe and North America.  Upon suc­cess­ful devel­op­ment and com­mer­cial­iza­tion of ATIR™ in the European mar­ket, Kiadis Pharma can receive addi­tion­al mile­stone pay­ments and is enti­tled to roy­al­ties on prod­uct sales.

“We are very pleased to have Hospira as a part­ner bring­ing exten­sive phar­ma­ceu­ti­cal devel­op­ment exper­tise into the ATIR™ devel­op­ment pro­gram. Hospira’s com­mit­ment to com­mer­cial­ize ATIR™ will ulti­mate­ly accel­er­ate mak­ing this life­sav­ing prod­uct avail­able for patients,” says Manja Bouman, CEO of Kiadis Pharma.

“Hospira is excit­ed about the life­sav­ing poten­tial of this inno­v­a­tive hema­tol­ogy prod­uct,” said Andrew Robbins, vice pres­i­dent, cor­po­rate devel­op­ment and pro­pri­etary phar­ma­ceu­ti­cal mar­ket­ing, “Following approval, ATIR will fit nice­ly with­in our strong port­fo­lio of oncol­o­gy prod­ucts, includ­ing biosim­i­lars Nivestim™ and Retacrit™, in Europe and Asia.”

 About Kiadis Pharma
Kiadis Pharma is an oncol­o­gy focused bio­phar­ma­ceu­ti­cal devel­op­ment com­pa­ny with cell based prod­ucts in clin­i­cal devel­op­ment.  The com­pa­ny devel­ops prod­ucts that offer nov­el treat­ment options for ter­mi­nal­ly ill can­cer patients and address sig­nif­i­cant unmet med­ical needs.  The key focus indi­ca­tion for Kiadis Pharma is lim­i­ta­tions and com­pli­ca­tions of bone mar­row trans­plan­ta­tion pro­ce­dures.  Kiadis Pharma is locat­ed in Amsterdam, The Netherlands. For more infor­ma­tion about Kiadis Pharma, please vis­it www.kiadis.com.

About ATIR™
ATIR™ is an inno­v­a­tive ther­a­py of donor T-lym­pho­cytes deplet­ed of allore­ac­tive T-cells and is infused after a patient receives a mis­matched hematopoi­et­ic stem cell trans­plan­ta­tion to reduce trans­plant relat­ed mor­tal­i­ty.  ATIR™ is designed to pre­vent severe acute graft-ver­sus-host dis­ease while pro­vid­ing an ear­ly immune recon­sti­tu­tion to fight infec­tions and remain­ing tumor cells, there­by reduc­ing trans­plant relat­ed mor­tal­i­ty and improv­ing over­all and dis­ease free sur­vival.  Moreover, it enables the use of a mis­matched, relat­ed (hap­lo-iden­ti­cal) donor, thus pro­vid­ing vir­tu­al­ly every­one with an imme­di­ate­ly avail­able donor, address­ing an urgent unmet med­ical need.  Today patients eli­gi­ble for allo­gene­ic trans­plan­ta­tion, but with­out a matched donor, have no treat­ment options.  ATIR™ can be con­sid­ered a tru­ly per­son­al­ized med­i­cine because it is pre­pared specif­i­cal­ly for each patient. 
Patients are cur­rent­ly being enrolled in a multi­na­tion­al, reg­is­tra­tion clin­i­cal tri­al of ATIR™, with sites in Europe and North America.  The tri­al is expect­ed to be com­plete­ly enrolled in the first part of 2011.  ATIR™ has orphan drug des­ig­na­tions from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

About Hospira
Hospira, Inc. is a glob­al spe­cial­ty phar­ma­ceu­ti­cal and med­ica­tion deliv­ery com­pa­ny ded­i­cat­ed to Advancing Wellness™. As the world leader in spe­cial­ty gener­ic injectable phar­ma­ceu­ti­cals, Hospira offers one of the broad­est port­fo­lios of gener­ic acute-care and oncol­o­gy injecta­bles, as well as inte­grat­ed infu­sion ther­a­py and med­ica­tion man­age­ment solu­tions. Through its prod­ucts, Hospira helps improve the safe­ty, cost and pro­duc­tiv­i­ty of patient care. The com­pa­ny is head­quar­tered in Lake Forest, Ill.,USA, and has approx­i­mate­ly 13,500 employ­ees. Learn more at www.hospira.com.

Leave a Reply

Your email address will not be published. Required fields are marked *